YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
(RTTNews) - Apollomics Inc. (APLM), a late-stage clinical biopharmaceutical company focused on oncology, has entered into definitive subscription agreements for a private placement transaction valued at approximately $10 million. The deal…
(RTTNews) - Today's top gainers in the biotech space include CareDx, which rallied after Medicare finalized its Local Coverage Determination process for molecular testing of solid organ allograft rejection; AtaiBeckley, after agreeing to b…
(RTTNews) - Today's biotech movers include Apollomics following its return to Nasdaq compliance, Iovance and AVITA ahead of Q2 earnings updates, Annexon, awaiting topline data in dry age-related macular degeneration with geographic atrophy…
Apollomics Inc. FOSTER CITY, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address…
(RTTNews) - Monday's top gainers include Tenon, following a Form S-1 filing; Azitra, which recently outlined its strategic reorientation and 2026 outlook; Nuvectis, after announcing a licensing deal with Haisco; and REGENXBIO, which is gea…
(RTTNews) - Apollomics Inc. (APLM) has entered into a $2.0 million unsecured convertible promissory note with Chairman and CEO Hung-Wen (Howard) Chen, providing short-term working capital to advance its clinical development programs and su…
Nasdaq's fair value estimate has seen a slight increase, rising from $102.35 to $103.13 per share. This adjustment follows a wave of positive analyst sentiment, which is driven by upgraded ratings and heightened price targets after strong…
FOSTER CITY, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”) (Nasdaq: APLM) announced today entering into a settlement agreement (the “Settlement Agreement” or the “Agreement”) with TWVC Goldlink P…
FOSTER CITY, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California-based late-stage clinical biopharmaceutical company, today announced the following update regarding changes…
加州福斯特城, Oct. 17, 2025 (GLOBE NEWSWIRE) -- 總部設於加州的 Apollomics Inc. (Nasdaq: APLM) (「Apollomics」或「公司」) 是一家晚期臨床生物製藥公司，開發多種腫瘤候選藥物對抗難以根治及對治療有抗藥性的癌症。該公司較早時宣佈已向 The Nasdaq Stock Market, LLC (簡稱「Nasdaq」) 之上市資格人員（簡稱「上市資格人員」）提交申請，對先前收到之除牌通知提出上訴，並要求在…
加利福尼亚州福斯特城, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq 代码：APLM，以下简称 “Apollomics” 或“公司”) 是一家总部位于加利福尼亚州的晚期临床阶段生物制药公司，致力于开发多种针对难治性和耐药性癌症的候选肿瘤药物。此前，该公司曾宣布已提交申请，拟就 Nasdaq Stock Market, LLC (以下简称“Nasdaq”) 上市资格部门（以下简称“部门”）此前发出的退市通知…
FOSTER CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California based late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address…
FOSTER CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California based late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address…
加州福特斯城, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (「Apollomics」或「該公司」) 今日發佈了以下公司營運的最新消息。 Apollomics 是一家臨床階段生物科技公司，致力推進創新腫瘤療法，為療選擇不多或別無選擇的患者改變治療格局。該公司的產品線擁有九種候選產品，涵蓋 11 項計劃，當中包括六項處於臨床開發階段的計劃。該公司專注於對抗肺癌、腦癌及其他實體腫瘤等最棘手的癌…
加州福特斯城, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq：APLM) (简称“Apollomics”或“公司”) 今日发布以下公司运营更新。 Apollomics 是一家临床阶段的生物技术公司，致力于推进创新肿瘤疗法，以改变那些治疗选择稀少或毫无选择的患者的治疗格局。公司目前在 11 个项目中拥有 9 款在研候选药物，其中 6 款处于临床开发阶段，专注研发用于治疗肺癌、脑癌及其他实体瘤等具有挑战性的癌…
NEW YORK, Oct. 14, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading will resume in Apollomics Inc. Class A ordinary shares (Nasdaq: APLM) and warrants (Nasdaq: APLMW) at 9:00 a.m. and 9:05 a.m. Easter…
FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), today announced the following company operational update. Apollomics is a clinical-stage biotechnology company advancing…
NEW YORK, Sept. 17, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading was halted on September 17, 2025 in Apollomics Inc., Ltd. at 14:37:17 Eastern Time for additional information requested from the co…
Strategic collaboration with LaunXP for the development of vebreltinib in combination with an EGFR inhibitor (“EGFRi”) to bring in $10 million upfront payment and expand dataset to combination therapyNew interim data for the vebreltinib de…
LaunXP receives exclusive development and commercialization rights for vebreltinib in combination with an EGFR inhibitor in Asia (excluding mainland China, Hong Kong and Macau) for the treatment of non-small cell lung cancer (“NSCLC”)Apoll…
FOSTER CITY, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-res…
FOSTER CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment…
Apollomics’ partner, Avistone Biotechnology, received approval from Chinese National Medical Products Administration (NMPA) to commercialize vebreltinib (APL-101) in China Compelling clinical data serving as basis of this approval supports…
FOSTER CITY, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cance…
FOSTER CITY, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), today announced a report by the Veneto Institute of Oncology on the efficacy response of a patient treated with vebreltinib for GBM with…
FOSTER CITY, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), today announced the presentation of vebreltinib efficacy and safety data from the KUNPENG clinical trial at the European Society of Medi…
FOSTER CITY, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment…
Phase2datafromvebreltinib(APL-101),ahighlyselectivecMetinhibitor,inpatientswithNSCLCwith MET exon14 skipping mutation expected second half 2023 Approximately$52.6millionincash,cashequivalents,andinvestmentsatJune30,2023;Cashrunwayto mid-ye…
FOSTER CITY, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-re…
Some of the most promising penny stocks are up-and-coming and just just getting started. The world of penny stocks is all about speculating which young firms have the potential to become the next big companies. The risk is well known. Penn…
FOSTER CITY, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant canc…
FOSTER CITY, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-re…